A detailed history of Nebula Research & Development LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Nebula Research & Development LLC holds 10,328 shares of EXAS stock, worth $727,607. This represents 0.07% of its overall portfolio holdings.

Number of Shares
10,328
Holding current value
$727,607
% of portfolio
0.07%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$41.33 - $74.26 $426,856 - $766,957
10,328 New
10,328 $436 Million
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $160,068 - $240,051
3,392 New
3,392 $230 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $12.5B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Nebula Research & Development LLC Portfolio

Follow Nebula Research & Development LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nebula Research & Development LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nebula Research & Development LLC with notifications on news.